ADPKD

#NephMadness 2020 The Impact of Genetic Testing on A Person: A Patient Perspective

March 31, 2020 // 0 Comments

@KidneyRebel is a patient with ADPKD who wishes to remain anonymous at this time for personal reasons. They are a staunch advocate for progress and innovation in nephrology and regularly engages on #NephTwitter. Competitors for the Genetics Region [read more...]

Clinical Trial End Points in ADPKD

June 6, 2019 // 0 Comments

Despite our current understanding regarding the pathophysiology of autosomal dominant polycystic kidney disease (ADPKD), only one therapy has been approved by the US FDA. There has been recent interest in redefining end points for clinical trials [read more...]

Predicting Polyuria: Can We Help Patients with ADPKD Better Tolerate Tolvaptan?

May 6, 2019 // 0 Comments

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease, often results in the need for renal replacement therapy, and is the etiology for renal failure in 10% of dialysis patients. Few treatment options [read more...]

Advancing Patient-Centered Care in Autosomal Dominant Polycystic Kidney Disease

January 25, 2018 // 1 Comment

In a recent study published in AJKD, Oberdhan et al (Open Access) discuss the development of a new health-related quality of life (HRQoL) tool for patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients. The name of the [read more...]

AJKD Blog

Official Blog of the American Journal of Kidney Diseases

ADPKD

#NephMadness 2020 The Impact of Genetic Testing on A Person: A Patient Perspective

Clinical Trial End Points in ADPKD

Predicting Polyuria: Can We Help Patients with ADPKD Better Tolerate Tolvaptan?

Advancing Patient-Centered Care in Autosomal Dominant Polycystic Kidney Disease